Login to Your Account

Spero pads syndicate, lands $51.7M series C for pipeline of antibacterials

By Marie Powers
News Editor

Thursday, March 9, 2017

Spero Therapeutics LLC completed a $51.7 million series C preferred financing led by new investor GV (formerly Google Ventures) with the participation of additional new investors RA Capital Management and Rock Springs Capital as well as existing investors, including Atlas Venture, S.R. One Ltd., MRL Ventures Fund, Lundbeckfonden Ventures, the Kraft Group and Osage University Partners.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription